Study guide
8.2 Osteoarthritis, Gout & Hyperuricemia
Board Certified Ambulatory Care Pharmacist BCACP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Patient Care Process
1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence
2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia
2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons
3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation
3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
4 Chapter 4: Endocrine & Metabolic Disorders
4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing
5 Chapter 5: Respiratory Care & Pulmonology
5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling
6 Chapter 6: Renal, Urological & Reproductive Health
6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity
7 Chapter 7: Neuropsychiatry & Behavioral Health
7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders
8 Chapter 8: Pain Management & Rheumatology
8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy
9 Chapter 9: Infectious Diseases & Immunizations
9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations
10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety
10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety
11 Chapter 11: Biostatistics, Study Design & Literature Evaluation
11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics
12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery
12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest
8.2 Osteoarthritis, Gout & Hyperuricemia
Key Takeaways Explain This Topic AI
2019 ACR Osteoarthritis Guidelines establish topical NSAIDs (diclofenac gel/patch) as strongly recommended first-line therapy for knee OA due to equivalent efficacy to oral NSAIDs with minimal systemic absorption (~5–10%) and superior GI/renal/cardiovascular safety.
Systemic oral NSAIDs require strict risk triage: high GI risk warrants celecoxib plus a proton pump inhibitor (PPI); cardiovascular risk is lowest with naproxen but all NSAIDs carry boxed warnings for MI, stroke, and heart failure; avoid oral NSAIDs in advanced CKD (eGFR <30 mL/min).
Acute gout flares require initiating anti-inflammatory therapy within 24 hours (low-dose colchicine 1.2 mg then 0.6 mg 1 hour later, high-dose oral NSAIDs, or systemic/intra-articular corticosteroids), and baseline urate-lowering therapy (ULT) must never be interrupted during an acute flare.
Urate-Lowering Therapy (ULT) is strongly indicated for ≥1 subcutaneous tophus, radiographic joint damage, or frequent flares (≥2/year), with a universal treat-to-target serum uric acid goal of <6.0 mg/dL (<5.0 mg/dL if tophi present).
Allopurinol is the preferred first-line ULT (starting at 100 mg daily or ≤50 mg in CKD), requiring pre-treatment HLA-B*5801 screening in patients of Southeast Asian and African American descent to prevent life-threatening Severe Cutaneous Adverse Reactions (SCAR/DRESS), paired with mandatory 3- to 6-month anti-inflammatory flare prophylaxis.
Last updated: September 2026
Osteoarthritis, Gout & Hyperuricemia
Executive Summary: Osteoarthritis (OA) and gout represent two of the most prevalent and debilitating rheumatologic disorders encountered in ambulatory care. The American College of Rheumatology (ACR) guidelines emphasize evidence-driven pharmacotherapy hierarchies: for osteoarthritis, topical NSAIDs represent the first-line standard for knee OA , minimizing systemic gastrointestinal, cardiovascular, and renal toxicities associated with oral NSAIDs. For gout, clinical mastery centers on the acute termination of inflammatory flares within 24 hours, followed by long-term treat-to-target (T2T) Urate-Lowering Therapy (ULT) aiming for a serum uric acid (SUA) < 6.0 mg/dL (or < 5.0 mg/dL in tophaceous disease). Ambulatory pharmacists play a pivotal role in performing pre-allopurinol HLA-B*5801 pharmacogenomic screening , titrating xanthine oxidase inhibitors, and co-prescribing mandatory anti-inflammatory prophylaxis to suppress mobilization flares.
1. 2019 ACR Guidelines for the Management of Osteoarthritis (OA)
Osteoarthritis is a whole-joint disease characterized by progressive breakdown of articular cartilage, subchondral bone remodeling, osteophyte formation, and low-grade synovial inflammation. It primarily affects weight-bearing joints (knees, hips) and hands (distal interphalangeal [DIP], proximal interphalangeal [PIP], and 1st carpometacarpal [CMC] joints).
Non-Pharmacological Foundations (Core First-Line for All OA)
Strongly Recommended: Aerobic and resistance exercise, aquatic exercise, weight loss (for knee and hip OA; achieving ≥5% to 10% weight loss produces profound biomechanical joint unloading and symptomatic relief), self-efficacy and self-management programs, tai chi, cane use (held in the hand contralateral to the affected joint), and tibiofemoral knee braces.
Conditionally Recommended Against: Acupuncture, Transcutaneous Electrical Nerve Stimulation (TENS), modified shoes, and lateral/medial wedge insoles.
Pharmacological Hierarchy in Osteoarthritis
Medication Class Guideline Recommendation & Joints Dosing & Administration Clinical Pearls & Pharmacological Nuances
Topical NSAIDs Strongly Recommended: Knee OA ; Conditionally Recommended: Hand OA Diclofenac 1% gel (Voltaren): ; • Lower extremity (knee): 4 g QID (max 16 g/joint/day); • Upper extremity (hand): 2 g QID (max 8 g/joint/day); • Total body max: 32 g/day First-line choice over oral NSAIDs for knee OA. Systemic absorption is only 5% to 10% of oral bioavailability. Excellent safety in older adults (≥75 years) and patients with GI/CV/renal risk factors.
Oral NSAIDs Strongly Recommended: Knee, Hip, Hand OA Lowest effective dose for shortest duration.; • Ibuprofen 400–800 mg TID; • Naproxen 250–500 mg BID; • Meloxicam 7.5–15 mg daily; • Celecoxib 100–200 mg daily Most effective oral agents for pain and stiffness. Requires formal gastrointestinal, cardiovascular, and renal risk stratification before initiation.
Intra-Articular Glucocorticoids Conditionally Recommended: Knee, Hip OA Triamcinolone acetonide (Kenalog) 20–40 mg or Methylprednisolone (Depo-Medrol) 20–40 mg per joint Provides rapid, short-term relief ( 4 to 8 weeks ). Limit frequency (avoid injecting same joint more than every 3 months; frequent repetitive injections may accelerate cartilage loss).
Duloxetine (SNRI) Conditionally Recommended: Knee OA, Multi-joint OA 30 mg PO daily for 1–2 weeks, then titrate to 60 mg PO once daily Centrally acting analgesic. Preferred in patients with comorbid fibromyalgia, neuropathic pain, or depression, or when NSAIDs are contraindicated. Avoid in severe hepatic/renal impairment (CrCl <30 mL/min).
Chondroitin Sulfate Conditionally Recommended: Hand OA ONLY 800–1200 mg PO daily Conditionally recommended against in knee and hip OA. Glucosamine is strongly/conditionally recommended against in all OA due to lack of clinical efficacy.
Acetaminophen (APAP) Conditionally Recommended: Knee, Hip, Hand OA 325–650 mg Q4–6H (Max 3,000–4,000 mg/day; max 2,000 mg/day in chronic hepatic impairment/alcoholism ) Small effect size and inferior to oral NSAIDs in clinical trials. Useful only as adjunct or when NSAIDs are strictly contraindicated. Monotherapy often insufficient.
Opioid Analgesics Strongly Recommended AGAINST (Non-tramadol opioids) ; Conditionally Recommended: Tramadol Tramadol 25–50 mg Q6H PRN (max 300–400 mg/day) Non-tramadol opioids offer poor risk-benefit profile with no long-term functional gain. Tramadol reserved only when all other therapies fail/contraindicated while awaiting joint arthroplasty.
2. Systemic NSAID Risk Stratification: GI, Renal & Cardiovascular Safety
When oral NSAIDs are indicated for OA or musculoskeletal pain, the ambulatory pharmacist must systematically assess three major organ toxicity domains: ORAL NSAID MULTI-ORGAN TOXICITY TRIAGE
- ┌───────────────────────────────────┼───────────────────────────────────┐
- ▼ ▼ ▼
- [ Gastrointestinal Risk ] [ Cardiovascular Risk ] [ Renal & Hemodynamic Risk ]
- Moderate Risk: Age >65, high • All NSAIDs increase MI, stroke, • Blocks COX-1/2 PGE2 / PGI2
- dose, history of uncomplicated and Heart Failure exacerbations. • Loss of compensatory afferent
ulcer, concurrent ASA/anticoag. • Boxed Warning for all NSAIDs. arteriolar vasodilation.
- ──> Add daily PPI or Misoprostol. • Naproxen has lowest thrombotic • Induces acute GFR decline,
- High Risk: Prior ulcer bleeding CV risk (PRECISION trial: low- fluid retention, hypertension,
──> Celecoxib + PPI, or avoid. dose celecoxib comparable). and hyperkalemia.
• Strictly AVOID in NYHA III-IV • Strictly AVOID in severe
heart failure or post-CABG. CKD (eGFR <30 mL/min).
1. Gastrointestinal Toxicity Mitigation
Mechanism: Non-selective NSAIDs inhibit COX-1, depleting mucosal prostaglandin E 2 E_2 E 2 ( P G E 2 PGE_2 PG E 2 ) and prostacyclin ( P G I 2 PGI_2 PG I 2 ), leading to decreased gastric mucus secretion, reduced bicarbonate production, diminished mucosal blood flow, and direct epithelial injury.
Moderate GI Risk Strategy: Co-prescribe a Proton Pump Inhibitor (PPI) (e.g., omeprazole 20 mg daily) or misoprostol with a non-selective NSAID, or utilize a COX-2 selective inhibitor (celecoxib, meloxicam).
High GI Risk Strategy: Utilize Celecoxib PLUS a PPI , or avoid oral NSAIDs entirely in favor of topical NSAIDs or non-systemic modalities.
2. Cardiovascular Toxicity Nuances
Mechanism: Selective COX-2 inhibition decreases endothelial prostacyclin ( P G I 2 PGI_2 PG I 2 , a potent vasodilator and platelet aggregation inhibitor) without inhibiting platelet COX-1-derived thromboxane A 2 A_2 A 2 ( T X A 2 TXA_2 TX A 2 , a vasoconstrictor and platelet activator), creating a pro-thrombotic state.
Comparative Safety: Naproxen (up to 500 mg BID) exhibits the most neutral cardiovascular thrombotic profile due to sustained platelet COX-1 inhibition throughout its 12-hour dosing interval. The landmark PRECISION trial demonstrated that moderate-dose Celecoxib (100–200 mg daily) was non-inferior to naproxen and ibuprofen regarding composite cardiovascular safety (MACE). However, all systemic NSAIDs induce sodium/water retention and can precipitate acute decompensated heart failure.
3. Renal Toxicity & Drug Interactions
Hemodynamic AKI: In states of decreased effective circulating arterial volume (CKD, heart failure, cirrhosis, volume depletion, ACEi/ARB therapy), glomerular filtration is maintained by prostaglandin-mediated afferent arteriolar vasodilation . NSAIDs constrict the afferent arteriole, precipitating acute prerenal azotemia.
The "Triple Whammy": Combining an ACE inhibitor or ARB + Diuretic + NSAID drastically increases the incidence of acute kidney injury (AKI) by concurrently lowering afferent perfusion, promoting efferent dilation, and inducing volume depletion.
3. Pathophysiology of Gout & 2020 ACR Diagnostic Criteria
Gout is an intensely painful inflammatory arthritis triggered by the crystallization of monosodium urate (MSU) in synovial fluid and periarticular tissues when serum uric acid (SUA) concentrations exceed the physiological saturation threshold ( > 6.8 mg/dL at normal body temperature and pH).
Pathophysiologic Mechanisms
Hyperuricemia Etiology: Uric acid is the end-product of purine degradation catalyzed by the enzyme xanthine oxidase : Hypoxanthine → Xanthine Oxidase Xanthine → Xanthine Oxidase Uric Acid \text{Hypoxanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Xanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Uric Acid} Hypoxanthine Xanthine Oxidase Xanthine Xanthine Oxidase Uric Acid
Underexcretion (~90% of patients): Impaired renal tubular clearance of uric acid mediated by transporters including URAT1 (SLC22A12) and GLUT9 (SLC2A9).
Overproduction (~10% of patients): Excessive purine intake (red meat, organ meats, shellfish, high-fructose corn syrup, beer/alcohol) or high cell turnover (myeloproliferative disorders, chemotherapy tumor lysis, psoriasis).
NLRP3 Inflammasome Activation: Phagocytosis of MSU crystals by synovial macrophages triggers the NLRP3 inflammasome complex , activating caspase-1 to cleave and release massive quantities of Interleukin-1 beta (IL-1β) , recruiting waves of neutrophils and causing severe acute inflammation.
Definitive Diagnosis: Arthrocentesis with polarized light microscopy demonstrating intracellular, negatively birefringent, needle-shaped monosodium urate crystals (appearing bright yellow when parallel to the compensating filter axis).
4. Acute Gout Flare Pharmacotherapy
Therapy for an acute gout flare must be initiated within 24 hours of symptom onset for optimal efficacy. Anti-inflammatory regimens must be continued until the flare completely resolves.
Critical Clinical Rule — Never Hold Baseline ULT: If a patient experiences an acute gout flare while already taking urate-lowering therapy (allopurinol, febuxostat), CONTINUE the baseline ULT without interruption or dose modification . Discontinuing ULT causes dramatic fluctuations in serum uric acid, prolonging and worsening the flare.
First-Line Monotherapy Regimens for Acute Gout Flares
Drug Regimen Acute Dosing Protocol Renal Adjustments & Precautions Key Adverse Effects & Contraindications
Colchicine 1.2 mg PO at first sign of flare, followed by 0.6 mg PO 1 hour later (Total = 1.8 mg over 1 hour).; Then continue 0.6 mg daily to BID starting 12 hours later until flare resolves. CrCl < 30 mL/min: Do not repeat acute flare treatment course more than once every 14 days . High-dose regimens ("dose to diarrhea") are obsolete. Severe GI toxicity (diarrhea, nausea, vomiting, abdominal cramping).
Oral NSAIDs High-dose anti-inflammatory therapy:; • Indomethacin: 50 mg PO TID; • Naproxen: 500 mg PO BID; • Celecoxib: 800 mg initial, then 400 mg PO BID Avoid in severe CKD (eGFR <30 mL/min), active peptic ulcer disease, or decompensated heart failure. Fluid retention, hypertension, GI bleeding, acute renal impairment. Taper rapidly upon symptom resolution.
Systemic Glucocorticoids Prednisone / Prednisolone: 0.5 mg/kg/day (e.g., 30 to 40 mg daily ) for 5 days, then stop; OR 30–40 mg daily for 5 days followed by a 5-day taper. Preferred first-line agent in patients with CKD, heart failure, or GI ulceration where NSAIDs and colchicine are contraindicated. Short-term hyperglycemia, insomnia, fluid retention, mood lability, blood pressure elevations.
Intra-Articular Corticosteroids Triamcinolone acetonide 10–40 mg injected into affected joint (dose depends on joint size). Ideal for acute monoarthritis or oligoarthritis involving 1–2 large accessible joints (e.g., knee, ankle). Must rule out septic arthritis via synovial gram stain and culture prior to injection.
Colchicine Drug-Drug Interactions & Severe Toxicities
Mechanism: Binds tubulin to inhibit microtubule polymerization, preventing neutrophil chemotaxis, adhesion, and phagocytosis.
CYP3A4 and P-Glycoprotein (P-gp) Boxed Warning: Colchicine is a major substrate of both CYP3A4 and P-gp. Co-administration with strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir) or strong P-gp inhibitors (cyclosporine) in patients with renal or hepatic impairment can cause fatal colchicine toxicity , characterized by severe bone marrow suppression, agranulocytosis, neuromyopathy, and rhabdomyolysis.
5. Chronic Treat-to-Target (T2T) Urate-Lowering Therapy (ULT)
Urate-lowering therapy reduces serum uric acid below the saturation point, dissolving existing crystal deposits, resolving tophi, preventing future flares, and halting joint damage.
ACR Indications for Initiating ULT ACR INDICATIONS FOR INITIATING ULT
[ STRONGLY RECOMMENDED ] [ CONDITIONALLY RECOMMENDED ]
Initiate ULT in ANY patient with: Consider ULT in patients with:
1. ≥ 1 Subcutaneous Tophus (tophi) • Infrequent flares (<2/year) BUT with:
- 2. Radiographic joint damage attributable to gout - CKD Stage ≥ 3 (eGFR <60 mL/min)
- 3. Frequent gout flares (≥ 2 flares per year) - Serum Uric Acid > 9.0 mg/dL
- History of Urolithiasis (kidney stones)
- [ CONDITIONALLY AGAINST ] ──> Asymptomatic Hyperuricemia (SUA >6.8 with NO flares or tophi)
- Treat-to-Target (T2T) Serum Uric Acid Goals
Standard Target: Maintain serum uric acid < 6.0 mg/dL (360 µmol/L) for all patients receiving ULT.
Tophi / Severe Erosive Gout Target: Maintain serum uric acid < 5.0 mg/dL (300 µmol/L) to accelerate crystal dissolution until all tophi have completely resolved.
First-Line & Alternative Urate-Lowering Medications
Drug & Class Mechanism of Action Dosing & Titration Schedule Special Precautions & Boxed Warnings
Allopurinol ; (Zyloprim); First-Line ULT Purine xanthine oxidase inhibitor (XO inhibitor) • Initial: 100 mg PO daily (or ≤ 50 mg daily in CKD Stage ≥ 3 ).; • Titration: Titrate every 2–5 weeks by 100 mg increments based on serial SUA until target <6.0 mg/dL achieved.; • Dose can exceed 300 mg daily (up to 800 mg daily ) with monitoring. HLA-B*5801 Genetic Screening required in high-risk populations. Risk of Allopurinol Hypersensitivity Syndrome (AHS).
Febuxostat ; (Uloric); Alternative XOI Non-purine selective xanthine oxidase inhibitor • Initial: 40 mg PO once daily.; • Titrate to 80 mg PO once daily if SUA remains >6.0 mg/dL after 2 weeks.; • No dose adjustment needed in mild-to-mod renal/hepatic impairment. FDA Boxed Warning for Cardiovascular Death (CARES trial). Reserve for patients who fail or cannot tolerate allopurinol.
Probenecid ; Uricosuric Agent Inhibits URAT1 in proximal tubule, blocking uric acid reabsorption • Initial: 250 mg PO BID for 1 week, then 500 mg PO BID (titrate up to 2 g/day). Ineffective if CrCl < 30 mL/min . Contraindicated in history of nephrolithiasis / urolithiasis . Counsel on 2–3 L/day fluid intake to prevent stones.
Pegloticase ; (Krystexxa); Recombinant Uricase Pegylated recombinant uricase converting uric acid to soluble allantoin • Dosing: 8 mg IV infusion every 2 weeks .; • Indicated for severe, refractory tophaceous gout. Boxed Warnings: Anaphylaxis & infusion reactions. Contraindicated in G6PD deficiency (hemolysis). Anti-drug antibodies develop; discontinue if pre-infusion SUA rises >6.0 mg/dL . Co-prescribe methotrexate to reduce immunogenicity.
Loading diagram... ACR Gout Urate-Lowering & Flare Prophylaxis Management Algorithm
- 6. Pharmacogenomics of Allopurinol & Mandatory Flare Prophylaxis
- HLA-B*5801 Pharmacogenomic Screening
The Clinical Risk: The HLA-B*5801 allele is strongly associated with Allopurinol Hypersensitivity Syndrome (AHS) and Severe Cutaneous Adverse Reactions ( SCAR ), encompassing Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). AHS carries a mortality rate of 20% to 25% .
Mandatory Pre-Screening Populations: The 2020 ACR guidelines strongly recommend testing for the HLA-B*5801 allele prior to initiating allopurinol in:
Patients of Southeast Asian descent with high allele frequency (Han Chinese, Korean, Thai ancestry).
African American patients (who exhibit higher population allele frequencies and higher rates of severe allopurinol-induced cutaneous toxicity than Caucasian populations).
Actionable Rule: If the patient tests positive for HLA-B*5801, allopurinol is strictly contraindicated . Use febuxostat as the alternative first-line xanthine oxidase inhibitor.
Critical Xanthine Oxidase Inhibitor Drug Interaction: Azathioprine & 6-Mercaptopurine
Both allopurinol and febuxostat potently inhibit xanthine oxidase, the primary metabolic pathway for azathioprine and 6-mercaptopurine (6-MP) .
Lethal Toxicity: Co-administration leads to massive accumulation of 6-thioguanine nucleotides, causing life-threatening, fatal pancytopenia and severe bone marrow aplasia .
Clinical Action: If an XOI must be co-administered with azathioprine or 6-MP, the dose of azathioprine/6-MP MUST be reduced by 67% to 75% (to 25%–33% of the original dose) , with frequent CBC monitoring.
Mandatory Anti-Inflammatory Flare Prophylaxis During ULT Initiation
The Paradoxical Flare Phenomenon: Initiating or titrating any urate-lowering therapy causes rapid dissolution and remodeling of articular MSU crystal deposits, shedding microcrystals into the synovial space and precipitating acute, severe "mobilization flares". Mobilization flares represent the #1 cause of early patient non-adherence and ULT discontinuation.
ACR Prophylaxis Regimens:
Colchicine 0.6 mg PO once daily or BID (preferred first-line; adjust for renal function/CYP3A4 inhibitors).
Low-dose NSAID (e.g., Naproxen 250 mg PO BID) co-prescribed with a gastroprotective PPI.
Low-dose Prednisone ( ≤ 10 mg PO daily \le 10\text{ mg PO daily} ≤ 10 mg PO daily ) if colchicine and NSAIDs are contraindicated.
Duration of Prophylaxis: Prophylaxis must be continued for at least 3 to 6 months after achieving target serum uric acid (<6.0 mg/dL), or continued for 6 months if subcutaneous tophi are present (or until all tophi have completely resolved).